www.aobiome.com
Open in
urlscan Pro
2606:4700:20::681a:c12
Public Scan
Submitted URL: http://www.aobiome.com/
Effective URL: https://www.aobiome.com/
Submission: On September 05 via api from US — Scanned from DE
Effective URL: https://www.aobiome.com/
Submission: On September 05 via api from US — Scanned from DE
Form analysis
0 forms found in the DOMText Content
Skip to content AOBiome * Our Science * AOB and it’s impact on Inflammatory Conditions, and related Systemic Effects * Published Articles and Papers * Pipeline * Press * Company News * Press Releases * Conferences and Events * About Us * Leadership * Board * Investors * Contact Us LIVE TOPICAL BIOTHERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY SKIN DISORDERS Learn More • LIVE TOPICAL BIOTHERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY SKIN DISORDERS Learn More AN EVOLUTIONARY APPROACH TO RESTORING HEALTH AOBiome Therapeutics is a late stage therapeutics company addressing a broad range of inflammatory skin conditions by harnessing a single strain of class defining Ammonia Oxidizing Bacteria (AOB), whose presence on the skin has been eliminated through modern living. RESTORING IMMUNE FUNCTIONALITY Ammonia Oxidizing Bacteria may serve to restore proper immune response through the down regulation of IL-4, IL-5, IL-13 and IL-31. Such markers are associated with inappropriate inflammatory response in several diseases including the pruritus (itch) pathway. AOBIOME CURRENTLY HAS MULTIPLE PHASE 2 CLINICAL PROGRAMS AOBIOME CURRENTLY HAS PHASE 2 CLINICAL PROGRAMS IN ACNE, ECZEMA AND ROSACEA. Learn More COMMITTED TO TRANSFORMING & IMPROVING HUMAN HEALTH We believe that the restoration of the symbiotic relationship between bacteria and humans will have a profound impact on human health. Clinical Trials Science Manufacturing Pipeline Clinical Trials Science Manufacturing About In the News May 10, 2022 · Cambridge, MA AOBiome’s CEO & President Todd Krueger featured in CEO/CFO Magazine Read More February 22, 2022 · Cambridge, MA AOBiome’s B244 demonstrated positive results from its Phase 2b trial for both Pruritus (Itch) and Appearance of Atopic Dermatitis (Eczema) Read More November 16, 2021 · Cambridge, MA AOBiome Achieves Landmark Recruitment Goal in Largest Clinical Trial Ever Powered by a Live Topical Biotherapeutic Read More Read More * Our Science * AOB and it’s impact on Inflammatory Conditions, and related Systemic Effects * Published Articles and Papers * Pipeline * Press * Company News * Press Releases * Conferences and Events * About Us * Leadership * Board * Investors * Contact Us © 2019 AOBiome | Terms & Conditions | Site Credits